- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
- 8-K Current report
- 2.1 Merger Agreement, Dated As of October 15, 2020, by and Among Gemini Therapeutics, Inc., Shareholder Representative Services LLC, FS Development Corp., and FSG Merger Sub Inc
- 3.1 Amended and Restated Articles of Certificate of Incorporation Gemini Therapeutics, Inc
- 3.2 Amended and Restated By-laws of Gemini Therapeutics, Inc
- 4.1 Form of Specimen Common Stock Certificate
- 10.2 Voting Agreement, Dated February 5, 2021, by and Among Gemini Therapeutics, Inc. and the Other Parties Thereto
- 10.3 Lockup Agreement, Dated February 5, 2021, by and Among Gemini Therapeutics, Inc. and the Other Parties Thereto
- 10.4 Gemini 2021 Stock Option and Incentive Plan
- 10.5 Forms of Award Agreements Under the Gemini 2021 Stock Option and Incentive Plan
- 10.6 Form of Indemnification Agreement for Directors of Gemini Therapeutics, Inc
- 10.7 Form of Indemnification Agreement for Executive Officers of Gemini Therapeutics, Inc
- 10.8 Form of Subscription Agreement
- 10.9 Employment Agreement, Dated January 21, 2021, by and Between Gemini Therapeutics, Inc. and Jason Meyenburg
- 10.10 Employment Agreement, Dated December 24, 2020, by and Between Gemini Therapeutics, Inc. and DR. Marc Uknis
- 10.11 Employment Agreement, Dated January 22, 2021, by and Between Gemini Therapeutics, Inc. and DR. Scott Lauder
- 16.1 Withum's Letter to the Securities and Exchange Commission, Dated February 11, 2021
- 21.1 List of Subsidiaries
- 99.1 Unaudited Pro Forma Condensed Combined Financial Information
- 99.2 Press Release
- 29 Mar 21 Gemini Therapeutics Reports Full Year 2020 Financial Results and Provides Business Update
- 29 Mar 21 Financial Statements and Exhibits
- 23 Feb 21 Departure of Directors or Certain Officers
- 11 Feb 21 Entry into a Material Definitive Agreement
- 5 Feb 21 Regulation FD Disclosure
- 3 Feb 21 Submission of Matters to a Vote of Security Holders
- 28 Jan 21 Other Events
Exhibit 16.1
February 11, 2021
Office of the Chief Accountant
Securities and Exchange Commission
100 F Street, NE
Washington, D.C. 20549
Ladies and Gentlemen:
We have read the statements of Gemini Therapeutics, Inc. included under Item 4.01 of its Form 8-K dated February 11, 2021. We agree with the statements concerning our Firm under Item 4.01, in which we were informed on February 5, 2021, of our dismissal following completion of the audit of FS Development Corp’s financial statements for the year ended December 31, 2020, which consists only of the accounts of the pre-Business Combination special purpose acquisition company (FS Development Corp.). We are not in a position to agree or disagree with other statements contained therein.
Very truly yours,
/s/ WithumSmith+Brown, PC
New York, New York